Walleye Capital LLC Buys New Shares in Sionna Therapeutics, Inc. $SION

Walleye Capital LLC purchased a new stake in Sionna Therapeutics, Inc. (NASDAQ:SION) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 97,347 shares of the company’s stock, valued at approximately $4,282,000. Walleye Capital LLC owned about 0.22% of Sionna Therapeutics at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Viking Global Investors LP increased its position in shares of Sionna Therapeutics by 8.2% in the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after acquiring an additional 242,427 shares during the last quarter. Jennison Associates LLC raised its holdings in Sionna Therapeutics by 30.1% during the first quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock worth $58,179,000 after acquiring an additional 335,942 shares in the last quarter. Vanguard Group Inc. boosted its position in Sionna Therapeutics by 3.7% during the fourth quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after purchasing an additional 41,797 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Sionna Therapeutics by 30.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 831,373 shares of the company’s stock valued at $34,203,000 after purchasing an additional 193,613 shares in the last quarter. Finally, State Street Corp grew its stake in Sionna Therapeutics by 188.7% in the fourth quarter. State Street Corp now owns 693,395 shares of the company’s stock valued at $28,526,000 after purchasing an additional 453,196 shares in the last quarter.

Sionna Therapeutics Stock Performance

Sionna Therapeutics stock opened at $6.46 on Friday. Sionna Therapeutics, Inc. has a 52 week low of $4.01 and a 52 week high of $54.97. The stock has a market capitalization of $292.07 million, a P/E ratio of -2.96 and a beta of 1.33. The stock has a 50-day simple moving average of $39.18 and a 200 day simple moving average of $39.18.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). Research analysts forecast that Sionna Therapeutics, Inc. will post -2.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on SION. Wall Street Zen cut Sionna Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Lifesci Capital cut shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 10th. Guggenheim cut shares of Sionna Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 10th. Stifel Nicolaus restated a “hold” rating and set a $7.00 target price on shares of Sionna Therapeutics in a report on Monday, August 10th. Finally, Freedom Capital lowered shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. One equities research analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $42.22.

Insider Activity at Sionna Therapeutics

In related news, Director Orbimed Advisors Llc sold 115,844 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total value of $5,270,902.00. Following the sale, the director owned 2,555,877 shares in the company, valued at approximately $116,292,403.50. This represents a 4.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 115,844 shares of the firm’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total value of $5,270,902.00. Following the sale, the director directly owned 2,555,877 shares of the company’s stock, valued at $116,292,403.50. This represents a 4.34% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 403,726 shares of company stock valued at $18,259,354 over the last quarter. 5.10% of the stock is currently owned by corporate insiders.

Sionna Therapeutics Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.